A retrospective trial in patients with multiple myeloma (MM) showed that patients who received 12 mg of pegfilgrastim were capable of mobilizing a sufficient number of CD34+ cells compared with patients who received G-CSF (18). This evidence concerns the gene CSF3 and Miyoshi myopathy.